Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Brickell Biotech Inc

BBI
Current price
0.9 USD -0.0048 USD (-0.53%)
Last closed 0.91 USD
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange NASDAQ
Capitalization 6 753 805 USD
Yield for 12 month 0.00 %
1Y
3Y
5Y
10Y
15Y
BBI
21.11.2021 - 28.11.2021

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado. Address: 5777 Central Avenue, Boulder, CO, United States, 80301

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

17.83 USD

P/E ratio

Dividend Yield

Current Year

+404 000 USD

Last Year

+1 822 000 USD

Current Quarter

+4 315 000 USD

Last Quarter

+92 000 USD

Current Year

+404 000 USD

Last Year

+1 822 000 USD

Current Quarter

+4 315 000 USD

Last Quarter

+92 000 USD

Key Figures BBI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -30 502 000 USD
Operating Margin TTM -657.53 %
PE Ratio
Return On Assets TTM -80.2 %
PEG Ratio
Return On Equity TTM -157.29 %
Wall Street Target Price 17.83 USD
Revenue TTM 4 643 000 USD
Book Value 5.81 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 2757.6 %
Dividend Yield
Gross Profit TTM -27 827 000 USD
Earnings per share -0.42 USD
Diluted Eps TTM -0.42 USD
Most Recent Quarter II 2022
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BBI

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BBI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:45
Payout Ratio
Last Split Date 05.07.2022
Dividend Date 03.09.2019

Stock Valuation BBI

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 1063.4404
Price Sales TTM 1.4546
Enterprise Value EBITDA 0.2799
Price Book MRQ 0.4099

Financials BBI

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BBI

For 52 weeks

0.56 USD 1.1 USD
50 Day MA 3 USD
Shares Short Prior Month 176 185
200 Day MA 8.13 USD
Short Ratio 0.62
Shares Short 189 595
Short Percent 6.73 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

441.58 USD Microsoft Corporation +0.8 (+0.18%)
Detailed analytics

ETF funds


S

SX7EEX

13.85 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) -0.35 (-2.26%)
Detailed analytics

Metals


Gold

2332.52 USD Gold +27.54 (+1.2%)
Detailed analytics